RECORD // Company

Serina Therapeutics, Inc.

Formerly: AgeX Therapeutics, Inc.

Built 2026-11-22T00:20:56Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (2 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

Gleif lei (1)
SEC EDGAR (1)
Matched by name only, not merged (2)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Serina Therapeutics · Ctgov · exact name match to 'Serina Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • SERINA THERAPEUTICS, INC. · USAspending · same registered legal name as 'Serina Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001708599-26-000068

ItemValuePeriodFormFiledAccessionReport
Revenue$125,0003 months ended 2026-09-3010-Q2026-11-120001708599-26-0000682026-11-22 00:20 UTCReport an error
Net income (loss)$-7,906,0003 months ended 2026-09-3010-Q2026-11-120001708599-26-0000682026-11-22 00:20 UTCReport an error
Interest expense$204,0003 months ended 2026-09-3010-Q2026-11-120001708599-26-0000682026-11-22 00:20 UTCReport an error
Cash and cash equivalents$19,403,000at 2026-09-3010-Q2026-11-120001708599-26-0000682026-11-22 00:20 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001708599
Ticker
SER
EIN
821436829
CUSIP
81751A108
Record ID
sx:sec:0001708599

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

34 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-12SEC EDGAR company profile2026-11-22 00:20 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-12SEC EDGAR company profile2026-11-22 00:20 UTCReport an error
State of incorporationAL2026-11-12SEC EDGAR company profile2026-11-22 00:20 UTCReport an error
Fiscal year end (MMDD)12312026-11-12SEC EDGAR company profile2026-11-22 00:20 UTCReport an error
Business address601 GENOME WAY, SUITE 2001, HUNTSVILLE, AL, 358062026-11-12SEC EDGAR company profile2026-11-22 00:20 UTCReport an error
ExchangesNYSE2026-11-12SEC EDGAR company profile2026-11-22 00:20 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$130,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:20 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-19,182,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:20 UTCReport an error
Total assets (at 2025-12-31)$6,951,0002025-12-3110-K, XBRL Assets2026-11-22 00:20 UTCReport an error
Stockholders' equity (at 2025-12-31)$-37,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:20 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$3,056,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:20 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-17,955,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:20 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$59,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:20 UTCReport an error
Operating lease liabilities (at 2025-12-31)$377,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:20 UTCReport an error
Form D total offering amount (D filed 2019-03-22)$5,000,0002019-03-22D2026-11-22 00:20 UTCReport an error
Form D total amount sold (D filed 2019-03-22)$4,500,0002019-03-22D2026-11-22 00:20 UTCReport an error
Form D industry groupBiotechnology2019-03-22D2026-11-22 00:20 UTCReport an error
Form D revenue rangeDecline to Disclose2019-03-22D2026-11-22 00:20 UTCReport an error
Form D date of first sale2019-03-112019-03-22D2026-11-22 00:20 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-12)On November 12, 2026, the Company issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing…2026-11-12SEC EDGAR 8-K 0001708599-26-000069 (text as filed, excerpt)2026-11-22 00:20 UTCReport an error
8-K Item 5.03, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (filed 2026-10-09)On October 5, 2026, Serina Therapeutics, Inc. (the “Company”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware, pursuant to Section 151(g) of the General Corporation Law of the State of Delaware, eliminating from the Company’s First Amended and Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on April 10, 2025, as corrected by the Certificate of Correction filed on May 22, 2025 (together, the “Certificate of Designations”)…2026-10-09SEC EDGAR 8-K 0001708599-26-000060 (text as filed, excerpt)2026-11-22 00:20 UTCReport an error
8-K Item 8.01, Other Items (filed 2026-09-09)On September 9, 2026, the Company issued a press release announcing that the Independent Safety Monitoring Committee has completed its blinded review of Cohort 1 of the Company's ongoing Phase 1b registrational study of SER-252 in patients with advanced Parkinson's disease and has recommended that the study advance to Cohort 2. Cohort 1, which evaluated the lowest dose in the single-ascending-dose portion of the study, showed a pharmacokinetic profile consistent with the sustained apomorphine exposure SER-252 is designed to provide, along with sustained periods of improvement in motor function in individual patients on exploratory clinical measures. The Company expects to report topline…2026-09-09SEC EDGAR 8-K 0001708599-26-000054 (text as filed, excerpt)2026-11-22 00:20 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-08-27)On August 21, 2026, Serina Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of August 21, 2026, with Roth Principal Investments, LLC (“Roth Principal Investments”). Upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement, the Company will have the right, in its sole discretion, to sell to Roth Principal Investments up to $25,000,000 of newly issued shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), subject to certain conditions and limitations contained in…2026-08-27SEC EDGAR 8-K 0001708599-26-000051 (text as filed, excerpt)2026-11-22 00:20 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-08-27)The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. The shares of Common Stock that may be issued pursuant to the Purchase Agreement will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506(b) promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of…2026-08-27SEC EDGAR 8-K 0001708599-26-000051 (text as filed, excerpt)2026-11-22 00:20 UTCReport an error
Largest institutional holder #1 (13F as filed): Sio Capital Management, LLC$1,940,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #2 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$314,6642026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #3 (13F as filed): Waverly Advisors, LLC$130,9342026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #4 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$98,9552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #5 (13F as filed): Keel Point, LLC$41,7262026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #6 (13F as filed): NORTHERN TRUST CORP$40,2962026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #7 (13F as filed): VANGUARD FIDUCIARY TRUST CO$38,8172026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #8 (13F as filed): Avidian Wealth Enterprises, LLC$36,4722026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #9 (13F as filed): JANE STREET GROUP, LLC$29,9622026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error
Largest institutional holder #10 (13F as filed): STATE STREET CORP$24,7512026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:20 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.